[A25-17] Marstacimab (haemophilia B) – Benefit assessment according to §35a Social Code Book V
Last updated 24.04.2025
Project no.:
A25-17
Commission:
Commission awarded on 03.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Haematology
| Project no. | Title | Status |
|---|---|---|
| A25-16 | Marstacimab (haemophilia A) – Benefit assessment according to §35a Social Code Book V | Commission work started |